MDR Organisms — MRSA, VRE, ESBL, CRE & C. difficile

Overview & definition

The multidrug-resistant organisms (MDRO) are the bacteria resistant to the multiple antibiotic classes — the MRSA, the VRE, the ESBL, the CRE, and the C. difficile. The driver is the antibiotic selection pressure (the overuse, the broad-spectrum). The two pillars of the management: (1) the targeted antibiotic (the reserve agents — the vancomycin, the linezolid, the daptomycin, the colistin, the ceftazidime-avibactam) and (2) the infection control (the contact precautions, the isolation, the hand hygiene, the stewardship).[1]

MRSA (methicillin-resistant Staphylococcus aureus)

• The mechanism — the altered PBP2a (the mecA gene) → the low affinity for the beta-lactams → the resistant to the ALL the beta-lactams except the ceftaroline.[1]
• The treatment — the vancomycin (the workhorse), the linezolid (the MRSA + the VRE), the daptomycin (the NOT for the pneumonia — the surfactant), the clindamycin / the doxycycline (the SSTI only, the not the bacteraemia), the ceftaroline (the only beta-lactam active against the MRSA).[1]
• The sites — the SSTI, the bacteraemia, the endocarditis, the pneumonia (the HAP/VAP), the osteomyelitis.[1]

VRE (vancomycin-resistant enterococcus)

• The mechanism — the altered D-alanyl-D-alanine (the D-ala-D-lac, the VanA or the VanB gene) → the vancomycin can't bind → the resistant to the vancomycin (and the teicoplanin for the VanB). The E. faecium the commonest.[1]
• The treatment — the linezolid (the MRSA + the VRE), the daptomycin (the workhorse for the VRE bacteraemia — the NOT for the pneumonia), the tigecycline.[1]

ESBL (extended-spectrum beta-lactamases)

• The mechanism — the Gram-negatives (the E. coli, the Klebsiella, the Proteus) produce the enzymes that the hydrolyze the penicillins, the cephalosporins (the 1st to the 3rd generation), and the aztreonam.[1]
• The treatment — the carbapenems (the meropenem, the imipenem, the ertapenem) — the mainstay. The often resistant to the fluoroquinolones too. The newer the beta-lactamase-inhibitor combinations (the ceftazidime-avibactam) the for the some.[1]

CRE (carbapenem-resistant Enterobacteriaceae)

• The mechanism — the produce the carbapenemases (the KPC, the NDM, the OXA-48, the VIM, the IMP) → the hydrolyze the carbapenems (the meropenem, the imipenem, the ertapenem).[1]
• The treatment — the colistin (the polymyxin E), the polymyxin B, the tigecycline, the ceftazidime-avibactam (the for the KPC), the meropenem-vaborbactam, the aztreonam plus the avibactam (the for the metallo-beta-lactamases — the NDM). The often the last-resort.[1]
• The colistin nephrotoxicity and the neurotoxicity — the monitor the renal function. The newer the combinations (the ceftazidime-avibactam, the meropenem-vaborbactam) the less toxic and the more effective than the colistin for the some.[1]

C. difficile (the spore, the toxin)

• The mechanism — the spore-forming, the toxin A and the toxin B producer. The antibiotic-associated (the disrupted gut flora).[1]
• The treatment — the oral vancomycin or the fidaxomicin (the see the separate topic).[1]

The infection control

(the prevent the spread) [1]

• The contact precautions and the isolation (the single room).[1]
• The hand hygiene — the soap-and-water for the C. difficile (the spores); the alcohol gel the inadequate for the spores but the fine for the others.[1]
• The decolonization (the MRSA — the chlorhexidine wash, the intranasal mupirocin).[1]
• The antibiotic stewardship (the reduce the selection pressure — the narrow, the de-escalate, the stop the unnecessary).[1]
• The surveillance and the screening (the high-risk admissions).[1]

[1]

Red flags

The ESKAPE pathogens — the mnemonic

The ESKAPE mnemonic captures the six genera that escape the action of the common antibiotics and dominate the ICU's resistant-infection burden: Enterococcus faecium (the VRE), Staphylococcus aureus (the MRSA), Klebsiella pneumoniae (the ESBL and the KPC-CRE), Acinetobacter baumannii (the CRAB), Pseudomonas aeruginosa (the CRPA), and the Enterobacter spp (the inducible AmpC). They share three features — the intrinsic hardiness, the acquisition of the mobile resistance elements (the plasmids, the transposons, the integrons), and the biofilm formation on the indwelling devices — and they spread clonally within the unit unless the contact precautions, the surveillance, and the stewardship are enforced.[6][8]

[6] [8]

Resistance mechanisms in depth — the molecular basis

The Ambler beta-lactamase classification (the four classes)

The beta-lactamases are classified by the Ambler scheme into four molecular classes by the active-site mechanism. The classes A, C and D are the serine beta-lactamases (the active-site serine hydrolyses the beta-lactam ring); the class B are the metallo-beta-lactamases (MBL) — they require the zinc at the active site, which is why they are NOT inhibited by avibactam, vaborbactam, or relebactam (the novel inhibitors target the serine only) and why they hydrolyse nearly every beta-lactam EXCEPT aztreonam (the monobactam).[8]

[8]

The ESBLs — the CTX-M era

The extended-spectrum beta-lactamases hydrolyse the penicillins, the 1st-to-3rd-generation cephalosporins, and the monobactam (aztreonam) — but NOT the cephamycins or the carbapenems. They are inhibited (in vitro) by the clavulanate. The dominant family worldwide is the CTX-M (the cefotaximase-Munich) — and CTX-M-15 in particular — which has displaced the older TEM/SHV types and moved from the hospital into the community (the community-acquired ESBL UTI is now routine). The MERINO trial settled the empiric-therapy question for the ESBL bloodstream infection: a carbapenem, NOT piperacillin-tazobactam.[1]

The AmpC — the inducible chromosomal beta-lactamase

The Enterobacter cloacae complex, the Klebsiella (Enterobacter) aerogenes, the Serratia marcescens, the Citrobacter freundii, and the Morganella morganii carry a chromosomal, inducible AmpC. The exposure to a beta-lactam (especially the 3rd-generation cephalosporin — ceftriaxone, ceftazidime) induces the derepression of the AmpC promoter → the stably-derepressed mutant emerges within days → the cephalosporin now fails. Therefore: never treat a serious Enterobacter/Serratia/Citrobacter/Morganella infection with a 3rd-generation cephalosporin, even when the initial susceptibility panel shows susceptible (the inoculum and the induction will outgrow it). The stable drugs against the derepressed AmpC are the cefepime (the 4th-gen, stable to the AmpC), the cefpirome, and the carbapenem.[8]

The carbapenemases — KPC, NDM, OXA-48, VIM, IMP

The carbapenemases hydrolyse the carbapenems (meropenem, imipenem, ertapenem). The geography matters: [1]

• KPC (Klebsiella pneumoniae carbapenemase) — the class A enzyme; the dominant CRE mechanism in the Americas, southern Europe, Israel, China. Clonal spread on the ST258 K. pneumoniae. Treatable with the ceftazidime-avibactam, the meropenem-vaborbactam, the imipenem-relebactam.[8]
• NDM (New Delhi metallo-beta-lactamase) — the class B MBL; the dominant mechanism in the Indian subcontinent, the Balkans, the Middle East, now globally disseminated. Resistant to ALL the novel inhibitors EXCEPT that the aztreonam survives (the MBLs cannot hydrolyse the monobactam) — so aztreonam + ceftazidime-avibactam (the avibactam covers any co-carried ESBL/AmpC/KPC that would otherwise destroy the aztreonam).[6]
• OXA-48 — the class D enzyme; the dominant CRE mechanism in Turkey, North Africa, the Mediterranean, now spreading across Europe. Often the low-level carbapenem resistance (easy to miss on the routine MIC) but the ceftazidime-avibactam is active.[8]
• VIM, IMP — the other class B MBLs; less common than the NDM but the same treatment implications (aztreonam + CZA; cefiderocol).[8]

The MRSA — mecA, PBP2a, and the SCCmec cassette

The methicillin resistance in Staphylococcus aureus arises from the mecA (or the rarer mecC) gene carried on a mobile genetic cassette — the SCCmec (staphylococcal cassette chromosome mec). The mecA encodes the PBP2a (penicillin-binding protein 2a) — a transpeptidase with a low affinity for ALL beta-lactam antibiotics → the cell-wall synthesis continues in the presence of the methicillin, the flucloxacillin, and every cephalosporin. The single exception is ceftaroline — the 5th-generation cephalosporin whose bulky R-group side chain allows it to bind and inhibit the PBP2a. Some MRSA strains also carry the Panton-Valentine leukocidin (PVL) — a cytotoxin associated with the necrotising pneumonia and the recurrent skin/soft-tissue infection.[7]

The VRE — vanA and vanB and the altered target

The vancomycin resistance in the enterococci arises from the replacement of the terminal D-alanine-D-alanine (the vancomycin-binding target) with the D-alanine-D-lactate ester bond — which has a 1000-fold lower affinity for the vancomycin. The vanA operon confers the high-level vancomycin resistance (MIC ≥64) AND the teicoplanin resistance; the vanB confers the variable vancomycin resistance and the teicoplanin remains active. Enterococcus faecium (NOT faecalis) is the dominant VRE — driven by the hospital-adapted ST17 / CC17 clonal complex.[8]

Carbapenemase detection — phenotypic vs molecular

The detection of a carbapenemase determines whether a CRE will respond to the ceftazidime-avibactam (the KPC, the OXA-48) or need the aztreonam + CZA (the NDM). The two arms of the testing: [1]

[8]

The pragmatic message: know the local carbapenemase epidemiology AND send the molecular test early — the empiric ceftazidime-avibactam will cover the KPC and the OXA-48 but NOT the NDM, and the wrong choice in a CRE bacteraemia carries a measurable mortality penalty.[6]

Acinetobacter baumannii (CRAB) — the environmental survivor

The Acinetobacter baumannii is the environmental survivor — desiccation-tolerant, surviving on the dry surfaces for weeks, contaminating the ventilator circuits, the water taps, the bedside equipment. The carbapenem resistance (the CRAB) is driven by the OXA-23, OXA-24/40, OXA-58 carbapenemases (the class D), frequently compounded by the over-expressed intrinsic AmpC (ADC), the efflux pumps, and the porin loss. The clinical scenarios: the late-onset VAP in the long-stay ventilated patient, the CRBSI in the patient with multiple lines, the wound infection in the trauma/burn/military casualty, and the post-neurosurgical meningitis (the external ventricular drain).[8]

The treatment has historically been colistin- or polymyxin-B-based combination with the high-dose ampicillin-sulbactam (the sulbactam component has the intrinsic anti-Acinetobacter activity — up to 6–8 g/day of sulbactam) plus a carbapenem or a tigecycline. The sulbactam-durlobactam (durlobactam is a diazabicyclooctane beta-lactamase inhibitor that protects the sulbactam from the OXA carbapenemases) is now the targeted agent of choice for the CRAB. The cefiderocol retains the activity against many CRAB but the CREDIBLE-CR signalled a possible mortality excess in the CRAB subgroup — reserve it for the CRAB where the sulbactam-durlobactam is unavailable or the organism is susceptible only to cefiderocol. The source control (the line removal, the wound debridement, the device removal) is mandatory — the antibiotics alone rarely clear a device-associated CRAB.[6][3]

Pseudomonas aeruginosa (CRPA / DTR) — the opportunist

The Pseudomonas aeruginosa is the opportunist of the structurally-damaged lung (the bronchiectasis, the CF, the severe COPD on frequent antibiotics) and the burn/immunocompromised host. The resistance is multifactorial and often cumulative: the over-expressed intrinsic AmpC (Pdc), the OprD porin loss (the imipenem-specific resistance), the upregulated efflux pumps (MexAB-OprM, MexXY) (conferring the meropenem, the fluoroquinolone, the aminoglycoside resistance), the acquired VIM/IMP/NDM/GES carbapenemases, and the target modification (the DNA gyrase for the fluoroquinolones). When the isolate is non-susceptible to ALL the first-line agents (piperacillin-tazobactam, ceftazidime, cefepime, the carbapenems, the fluoroquinolones, the aminoglycosides) it is labelled the difficult-to-treat resistance (DTR-P. aeruginosa).[6]

The targeted agents for the CRPA: [1]

• Ceftolozane-tazobactam — the ceftolozane is a cephalosporin with the greatest intrinsic anti-pseudomonal potency and the stability against the AmpC; the tazobactam adds the ESBL cover. The first-line for the CRPA WITHOUT a carbapenemase. The ASPECT-NP established it for the HAP/VAP.[6]
• Cefiderocol — the siderophore cephalosporin (uses the iron-transport active uptake to cross the outer membrane); active against many CRPA including some MBL-producers. The CREDIBLE-CR is the evidence.[3]
• Colistin / polymyxin B — the reserve; the nephrotoxicity the dose-limiting toxicity.
• Ceftazidime-avibactam — only if the resistance is KPC/ESBL-driven; the avibactam has NO useful activity against the AmpC of Pseudomonas (and none against the MBL).[8]

Enterobacter spp & the inducible AmpC — the derepression trap

The Enterobacter cloacae complex, the Klebsiella aerogenes (formerly Enterobacter aerogenes), the Citrobacter freundii, the Serratia marcescens, and the Morganella morganii share a chromosomal inducible AmpC — the "SPICE/M" organisms (Serratia, Pseudomonas/Proteus-indole-positive, Indole-positive Providencia, Citrobacter, Enterobacter, Morganella). The trap: the 3rd-generation cephalosporin (ceftriaxone, ceftazidime) initially appears susceptible on the panel, but the treatment selects the stably-derepressed mutant within 3–4 days → the cephalosporin fails with a breakthrough bacteraemia. The safe empiric options for a serious SPICE/M infection are the cefepime (4th-gen, stable to the derepressed AmpC), the cefpirome, or the carbapenem; the fluoroquinolone and the cotrimoxazole susceptibility must be confirmed. The piperacillin-tazobactam is borderline (acceptable for some, avoided for the high-inoculum BSI/endocarditis).[8]

The newer Gram-negative agents — when to use what

The post-2015 antibacterial armamentarium is the most-tested "new drugs" topic in the CICM/FFICM exam. The choice rests on the carbapenemase class and the pathogen.[6]

[6] [8] [2] [11]

The MERINO evidence — piperacillin-tazobactam is NOT adequate for the ESBL BSI

[1]

INCREMENT-CPE — the combination therapy and the mortality-predictor score

[2]

CREDIBLE-CR — cefiderocol for the carbapenem-resistant Gram-negatives

[3]

TANGO II — meropenem-vaborbactam for the CRE

[4]

IGNITE4 — eravacycline for the complicated intra-abdominal infection

[5]

Infection control deep-dive — cohorting, screening, decolonisation, environment

The two pillars of the MDRO management are the targeted antibiotic and the infection control. The infection-control arm is what stops the MDRO reaching the next patient — every gap here is measured in the additional colonised/infected patients downstream.[8]

Contact precautions and the single room

• Single-room isolation with a dedicated toilet and dedicated equipment (stethoscope, BP cuff, thermometer) for every patient colonised or infected with an MDRO.
• Gown and gloves on entry to the room (the donning BEFORE contact, the doffing BEFORE exit). The gown protects the uniform — the uniform is the vector to the next bed.
• Duration: until discharge for the VRE and the CRE (the decolonisation is ineffective and the recrudescence common); for the MRSA the precautions may be discontinued after the documented decolonisation AND repeat negative screens. [1]

Hand hygiene — the alcohol vs the soap-and-water

• Alcohol-based hand rub is the mainstay for the MRSA, the VRE, the ESBL, the CRE — fast, well-tolerated, evidence-based.
• SOAP-AND-WATER is mandatory for C. difficile and Norovirus — the alcohol does NOT kill the spores. Wash hands with soap and water after every contact with a C. difficile patient; the alcohol rub is acceptable IN ADDITION but NOT as a substitute.
• The five moments of hand hygiene (WHO): before patient contact, before aseptic task, after body-fluid exposure, after patient contact, after contact with the surroundings. [1]

Screening and the admission surveillance

• Targeted admission screening for the high-risk admissions: the patient transferred from an overseas hospital (especially India, SE Asia, the Middle East, southern Europe), the patient with a prior MDRO history, the long-term-care-facility resident, the patient with a recent hospitalisation or recent broad-spectrum antibiotics in the last 3–12 months.
• Sites: rectal/perianal swab (the carriage site for VRE, CRE, ESBL); nares + groin/perianal (MRSA); sputum/respiratory (MRSA, CRPA, CRAB if colonised); wound/drain sites.
• Active surveillance cultures repeated weekly during the ICU stay for the high-prevalence units (catches the ICU-acquired acquisition). [1]

Cohorting

When the single rooms run out, cohort — place the patients with the SAME MDRO in the same bay/room, with dedicated staff (the cohort nursing: one team for the MDRO-positive bay, a different team for the negative). NEVER cohort the patients with different MDROs together (the co-colonisation and the plasmid transfer accelerate the resistance). The dedicated equipment and the terminal cleaning between patients are still required. [1]

Environmental cleaning and the terminal disinfection

The MDRO survive on the inanimate surfaces: the Acinetobacter for weeks, the VRE and the MRSA for days, the C. difficile spores for months. The daily cleaning with a hospital-grade disinfectant and the terminal cleaning (after discharge/transfer) are non-negotiable. For C. difficile the disinfectant must be sporicidal (bleach / hypochlorite 1000 ppm, or the hydrogen peroxide vapour). The ultraviolet-C and the hydrogen-peroxide vapour are adjuncts for the terminal clean. The hand-touch surfaces (bed rails, call buttons, IV pumps, keyboards) are the highest-yield targets. [1]

Decolonisation — MRSA yes, VRE and CRE no

• MRSA decolonisation: 2% chlorhexidine (CHG) body wash daily for 5 days + 2% mupirocin nasal ointment twice daily for 5 days, repeated for 2-3 cycles. Use for the pre-operative MRSA carrier (reduces the surgical-site infection) and the recurrent MRSA SSTI. Effect on the ICU-acquired MRSA transmission is modest but real in the high-prevalence settings.
• VRE and CRE decolonisation: NOT effective and NOT recommended — the gut colonisation persists, the recurrence after apparent clearance is the rule, and the antibiotics used risk selecting further resistance. Focus on the contact precautions, the cohorting, and the stewardship. [1]

Antimicrobial stewardship — the upstream prevention

The antibiotic selection pressure is the engine of the MDRO. The stewardship interventions that reduce the MDRO burden: the narrowing at 48-72 h (de-escalation by culture), the shortest effective duration (procalcitonin-guided stopping, oral switch), the formulary restriction of the broadest agents, the prior-authorization for the reserve agents, and the daily antibiotic review ("stop, change, or continue?" at every ward round). The reduction in the total antibiotic DOT (days-of-therapy) per 1000 patient-days is the most reliable single correlate of the falling MDRO rate.[8]

Vancomycin AUC-guided monitoring — the new standard for the MRSA

The 2020 ASHP/IDSA/PIDS/SIDP consensus moved the vancomycin dosing from trough-based to AUC-guided (area-under-curve / MIC). The target for the serious MRSA infection is an AUC₀₋₂₄ / MIC of 400-600 (assuming MIC ≤1 mg/L). The old trough 15-20 mg/L target was a poor surrogate — it underdosed some and overdosed others, and the vancomycin + piperacillin-tazobactam combination roughly TRIPLED the AKI rate (the vancomycin-related AKI is concentration-dependent and the piptazo potentiated it).[12][9]

[9] [12]

VRE treatment — linezolid vs daptomycin

The VRE (almost always the Enterococcus faecium) bacteraemia carries the mortality of the untreated Gram-positive sepsis. The two workhorses: [1]

[1]

The pragmatic choice: daptomycin for the VRE BSI / endocarditis (bactericidal, the workhorse); linezolid for the VRE pneumonia or the patient intolerant of daptomycin. AVOID the linezolid in the severe thrombocytopenia, the concurrent SSRI/MAOI, and the long (>14-day) course. AVOID the daptomycin in the pneumonia and the statin coadministration (CK/myopathy). [1]

Exam practice

[1] [1]

Additional clinical pearls — the CICM/FFICM/EDIC high-yield

Extended red flags — the errors that kill in the MDR infection

Region alert — the carbapenemase epidemiology by geography

The empiric choice for a CRE depends on the local carbapenemase — and the geography predicts it. Know the patient's travel and transfer history before choosing the empiric novel beta-lactam.[8]

[1]

The expanded one-paragraph viva answer

[1]

References

1. [1]Harris PNA, Tambyah PA, Lye DC, et al Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial JAMA, 2018.PMID 30208454
2. [2]Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study Lancet Infect Dis, 2017.PMID 28442293
3. [3]Bassetti M, Echols R, Matsunaga Y, et al Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial Lancet Infect Dis, 2021.PMID 33058795
4. [4]Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial Infect Dis Ther, 2018.PMID 30270406
5. [5]Solomkin JS, Ramesh MK, Cesnauskas G, et al Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial JAMA Surg, 2017.PMID 27851857
6. [6]Tamma PD, Aitken SL, Bonomo RA, et al Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections Clin Infect Dis, 2024.PMID 39108079
7. [7]Liu C, Bayer A, Cosgrove SE, et al Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children Clin Infect Dis, 2011.PMID 21208910
8. [8]Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, et al European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine) Clin Microbiol Infect, 2022.PMID 34923128
9. [9]Lim AS, Ho E, Tacey M, et al Area-Under-Curve-Guided Versus Trough-Guided Monitoring of Vancomycin and Its Impact on Nephrotoxicity: A Systematic Review and Meta-Analysis Ther Drug Monit, 2023.PMID 36728329
10. [10]Almangour TA, Alhammad AM, Alenzi F, et al Ceftazidime-Avibactam versus Colistin for the Treatment of Infections Due to Carbapenem-Resistant Enterobacterales: A Multicenter Cohort Study Infect Drug Resist, 2022.PMID 35125877
11. [11]Schmid A, Wolfensberger A, Nemeth J, et al Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis Sci Rep, 2019.PMID 31664064
12. [12]Hammond DA, Smith MN, Li C, et al Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam Clin Infect Dis, 2017.PMID 27940946
13. [13]Connolly LE, Riddle V, Cebrik D, et al A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis Antimicrob Agents Chemother, 2018.PMID 29378708